• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

    5/27/25 12:12:00 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email

    As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost

    TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ:PRFX).

    According to the agreement, which was completed in March 2025, Blade Ranger received a package of securities that included, among other things, common shares of PainReform representing approximately 9.9% of the company's equity, as well as approximately 3.08 million warrants convertible into common shares, some of which are subject to milestone achievements.

    Now, as a result of reaching the first milestone, the company has received 685,004 warrants exercisable at an exercise price of $0.01 per share, while PainReform's  shares are currently trading at approximately $1.91. Following receipt of these warrants, Blade Ranger holds shares and warrants (with a $0.01 exercise price) worth approximately $2 million based on the share price at the time of this announcement.

    Blade Ranger's CEO commented:

    "The continued success of PainReform's software sales, which led to the maturity of additional warrants, significantly improves the company's financial flexibility and supports the accelerated business development we are driving forward."

    The market value of the shares that may be derived from the matured warrants, based on the current share price, is approximately NIS 4.5 million.

    Cision View original content:https://www.prnewswire.com/news-releases/blade-ranger-consideration-from-painreform-transaction-continues-to-mature-following-growth-in-software-sales-302466068.html

    SOURCE Blade Ranger Ltd.

    Get the next $PRFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy

    TEL AVIV, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group (Electricite' De France, France's Electric Company, one of the largest international energy companies), a global leader in renewable energy, relating to an operational, utility-scale solar power plant in Israel. This engagement represents the next phase of Deep Solar's previously announced strategy and a new commercial revenue opportunity—an important milestone following the recent launch of Smart TDD. Pursuant to the agre

    2/18/26 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

    TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (NASDAQ:PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy. Under the agreement, DeepSolar will provide continuous analytics and performance monitoring designed to enhance operational visibility, support proactive asset management, and enable data-driven decision-making throughout the proje

    2/11/26 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

    Patent filing follows acceptance into the NVIDIA Connect Program  Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for utility-scale solar assets TEL AVIV, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that it has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling designed to significantly improve the accuracy of solar energy production forecasts in competitive electric utility markets. The patent follows acceptance into the prestigious NVIDIA Connect Program and

    1/20/26 9:05:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/18/26 9:38:03 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/11/26 8:54:35 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/3/26 4:16:05 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care